IDXG (Interpace Biosciences) Cyclically Adjusted Revenue per Share: $14.38 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IDXG Interpace Biosciences Inc IDXG
41 GF Score
Price $1.61
GF Value $0.20
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Interpace Biosciences Cyclically Adjusted Revenue per Share?

Interpace Biosciences IDXG +2.55% 41 Cyclically Adjusted Revenue per Share is $14.38 as of Jun. 2026. GuruFocus rates IDXG with a GF Score™ of 41/100 and a GF Value™ of $0.20 (Significantly Overvalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Interpace Biosciences's adjusted revenue per share for the three months ended in Jun. 2026 was $0.329. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $14.38 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Interpace Biosciences's average Cyclically Adjusted Revenue Growth Rate was -37.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -49.80% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -48.40% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was -33.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Interpace Biosciences was -0.40% per year. The lowest was -58.70% per year. And the median was -15.90% per year.

As of today (2026-08-20), Interpace Biosciences's current stock price is $1.61. Interpace Biosciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was $14.38. Interpace Biosciences's Cyclically Adjusted PS Ratio of today is 0.11.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Interpace Biosciences was 0.19. The lowest was 0.01. And the median was 0.02.


Interpace Biosciences  (OTCPK:IDXG) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Interpace Biosciences's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1.61/14.38
=0.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Interpace Biosciences was 0.19. The lowest was 0.01. And the median was 0.02.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Interpace Biosciences Cyclically Adjusted Revenue per Share Related Terms


Interpace Biosciences Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Interpace Biosciences's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Interpace Biosciences Cyclically Adjusted Revenue per Share Chart

Interpace Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 244.87 149.06 24.96 26.17 18.87

Interpace Biosciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.07 21.08 18.87 16.90 14.38

IDXG vs PRPO, ADVB, BIOQ: Cyclically Adjusted Revenue per Share Comparison

For the Diagnostics & Research subindustry, Interpace Biosciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Interpace Biosciences Cyclically Adjusted PS Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Interpace Biosciences's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Interpace Biosciences's Cyclically Adjusted PS Ratio falls into.


IDXG
41GF Score
Interpace Biosciences Inc IDXG
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Interpace Biosciences Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Interpace Biosciences's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.329/333.9520*333.9520
=0.329

Current CPI (Jun. 2026) = 333.9520.

Interpace Biosciences Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 18.220 241.428 25.203
201612 16.785 241.432 23.217
201703 7.922 243.801 10.851
201706 3.991 244.955 5.441
201709 1.907 246.819 2.580
201712 1.570 246.524 2.127
201803 1.726 249.554 2.310
201806 1.970 251.989 2.611
201809 2.039 252.439 2.697
201812 2.038 251.233 2.709
201903 1.710 254.202 2.246
201906 1.644 256.143 2.143
201909 2.022 256.759 2.630
201912 1.100 256.974 1.430
202003 2.262 258.115 2.927
202006 1.350 257.797 1.749
202009 2.043 260.280 2.621
202012 2.387 260.474 3.060
202103 2.405 264.877 3.032
202106 2.719 271.696 3.342
202109 1.934 274.310 2.355
202112 2.178 278.802 2.609
202203 1.883 287.504 2.187
202206 1.749 296.311 1.971
202209 1.930 296.808 2.172
202212 1.951 296.797 2.195
202303 2.281 301.836 2.524
202306 2.555 305.109 2.797
202309 2.102 307.789 2.281
202312 2.301 306.746 2.505
202403 2.322 312.332 2.483
202406 2.736 314.175 2.908
202409 2.780 315.301 2.944
202412 2.815 315.605 2.979
202503 0.416 319.799 0.434
202506 2.087 322.561 2.161
202509 0.316 324.800 0.325
202512 0.333 324.054 0.343
202603 0.326 330.213 0.330
202606 0.329 333.952 0.329

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $14.38 mean?
Interpace Biosciences (IDXG) has a Cyclically Adjusted Revenue per Share of $14.38 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Interpace Biosciences and its competitors.
Is Interpace Biosciences' Cyclically Adjusted Revenue per Share too high?
Interpace Biosciences' current Cyclically Adjusted Revenue per Share is $14.38. Overall, Interpace Biosciences has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Interpace Biosciences' Cyclically Adjusted Revenue per Share compare to PRPO and ADVB?
Interpace Biosciences' Cyclically Adjusted Revenue per Share of $14.38 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Diagnostics & Research company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Diagnostics & Research industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Interpace Biosciences and its competitors. Interpace Biosciences's current Cyclically Adjusted Revenue per Share is $14.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Interpace Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Interpace Biosciences (IDXG) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.20, compared to a current price of $1.61 — trading 705% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is $14.38. Interpace Biosciences' overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Interpace Biosciences (IDXG), the current Cyclically Adjusted Revenue per Share is $14.38 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Interpace Biosciences (IDXG) Overvalued in 2026?

Based on GuruFocus' analysis, Interpace Biosciences stock appears to be overvalued. The current stock price of $1.61 is trading 705% above its estimated GF Value™ of $0.20. GuruFocus considers Interpace Biosciences to be Significantly Overvalued.

Key valuation signals for IDXG:

  • Cyclically Adjusted Revenue per Share: $14.38
  • GF Value™: $0.20 vs. price of $1.61 (705% above fair value)
  • GF Score™: 41/100 with 5 warning signs

No single metric tells the full story. See the IDXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Interpace Biosciences Business Description

Other Exchanges PF42:Germany
Address 2001 Route 46, Suite 310, Waterview Plaza, Parsippany, NJ, USA, 07054
Interpace Biosciences Inc provides esoteric molecular diagnostic testing and pathology services to aid physicians in evaluating cancer risk in patients with indeterminate biopsies and a perceived high risk of cancer based on clinical features. The company develops and commercializes genomic tests and related first-line assays that can personalize medicine and help improve patient diagnosis and management. Its clinical customers mainly consist of physicians, hospitals, cancer centers, commercial laboratories, pathology groups, and clinics. The various diagnostic tests offered by the company include ThyGeNEXT and ThyraMIRv2 for the detection of thyroid cancer.
41GF Score

Get the complete analysis for IDXG

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.61
Price
$0.20
GF Value